drugset

drugset / Trial / NCT02499848

Evaluate, Safety and Tolerability of Intraprostatic PRX302 Administration, Low to Intermediate Risk Prostate Cancer

NCT02499848 ↗

Phase 2 Completed 18 enrolled Sophiris Bio Corp

NaSingle-groupOpen-labelTreatment

Summary

To Evaluate Safety, Tolerability and Potential Efficacy of PRX302 effect on clinically significant localised low to intermediate prostate cancer.

Timeline

Start: 2015-07
Primary completion: 2016-06
Completion: 2016-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TOPSALYSIN	Unknown	—	Other

Indications